chromosome 12 open reading frame 42Genealiases: []
Q-omics provides the consensus-scored C12orf42 profile across patient tissues and cancer cell-line models. C12orf42 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, C12orf42 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, C12orf42 RNA expression shows 13,336 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, HNSC, and THYM as cancer lineages where C12orf42 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C12orf42 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C12orf42 survival associations across molecular data types. C12orf42 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C12orf42 RNA expression–survival associations across cancer types. High C12orf42 expression shows unfavorable associations in UCEC, but favorable associations in UCS, READ, PAAD, THYM and LUAD. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for C12orf42 RNA expression.
This table summarizes C12orf42 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for C12orf42. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C12orf42 shows higher tumor expression in HNSC, LUAD, LUSC, BRCA, KIRC and STAD. The HNSC box plot shows higher C12orf42 RNA expression in tumor versus normal tissue (log2 FC = +0.249, t-test p < 0.001).
This table shows molecular features associated with C12orf42 in patient tissues and cancer cell lines. In patient samples, C12orf42 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, C12orf42 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and LUNG_SCLC.
